The World Marrow Donor Association (WMDA) plays a crucial role in providing essential starting materials for cell and gene therapy. As these innovative therapies evolve, access to high-quality, compliant starting materials is essential to drive progress in both research and clinical applications. At WMDA, we connect researchers, clinicians, and biopharmaceutical companies with a global network of stem cell donors and cord blood units, helping to ensure the availability of raw materials for these cutting-edge treatments.

WMDA provides access to a vast, diverse pool of stem cell and cord blood donors from certified organisations worldwide. Our network includes over 42 million volunteer donors and 800,000 cord blood units available for transplantation, which are also used as starting materials for gene-modified cell therapies.

The materials provided by WMDA members are carefully managed under stringent ethical and medical standards. Our partnership with certified donor registries and cord blood banks ensures that all starting materials meet regulatory requirements, are fully compliant with International Ethical Standards, and are prepared for use in cell and gene therapies.

 

The need for diverse and specialized cell populations for cell and gene therapies is growing. Through our established network, WMDA Bio-Informatics Speciaists can assist you with special requests and provid you advice on HLA frequencies.

WMDA’s streamlined Search & Match Service provides quick and efficient matching of starting materials to meet the needs of research and clinical applications, helping speed up the process of cell and gene therapy development.